Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eddingpharm Acquires ACT Biotech for $95 Million

publication date: Jan 8, 2014
Eddingpharm, a China drug company known mostly for in-licensing China distribution rights, acquired all the assets of San Francisco-based ACT Biotech, including worldwide ownership of three cancer-targeting small molecule drug candidates. The most advanced of the three, Telatinib, completed a successful US Phase II trial in gastric cancer patients in 2011. It has been granted Orphan Drug status by the FDA. Total consideration for the deal, including upfront and milestone payments, may reach up to $95 million. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital